Plain-English translation of NCT02740335 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Anticoagulation reversal research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested , a medication designed to reverse the effects of blood-thinning drugs in patients who needed emergency surgery. The study compared to an existing blood-clotting medication called Kcentra to see if the new treatment worked just as well at stopping dangerous bleeding during surgery.
Patients taking blood-thinning medications (like warfarin) who suddenly need emergency surgery face a serious problem: their blood cannot clot normally, putting them at high risk of life-threatening bleeding. This medication was developed to quickly reverse this blood-thinning effect so surgeons can safely operate.
Participants received a single intravenous infusion of either or Kcentra in the hours before their urgent surgery. The study then monitored how well the medication reversed their blood-thinning effect and how safely they tolerated the treatment during and after surgery.
AI-generated summary from trial data · Sep 24, 2026 · Not medical advice
United States